$Nuvation Bio(NUVB.US)$ NEWS Nuvation Bio Completes Acquisition of AnHeart Therapeutics Nuvation Bio completes the acquisition of AnHeart Therapeutics, transforming into a late-stage global oncology company. Shareholders now own approximately 67% and 33% of NUVB, setting the stage for potential commercial success by 2025.
Gainers: •$Axsome Therapeutics(AXSM.US)$+39.1% (received from FDA proposed labeling for the its AXS-05 product candidate with respect to its New Drug Application for AXS-05 for the treatment of major depressive disorder) •$Capricor Therapeutics(CAPR.US)$+4% (announces statistically significant clinical benefits in skeletal muscle function in non-ambulant duchenne muscular dystrophy patients treated with CAP-1002 in HOPE-2 Open L...
Nuvation Bio股票討論區
NEWS
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
Nuvation Bio completes the acquisition of AnHeart Therapeutics, transforming into a late-stage global oncology company. Shareholders now own approximately 67% and 33% of NUVB, setting the stage for potential commercial success by 2025.
⇒ $137.5M deal at $20.42/sh 💰💰
⇒ strengthens portfolio in inflammatory & autoimmune diseases
⇒ Adds lead asset NX-13 (Ph2 trial UC)
$Nuvation Bio(NUVB.US)$ to acquire AnHeart Therapeutics
⇒ all-stock transaction
⇒ transforms NUVB into late-stage global oncology company
⇒ Includes taletrectinib with ongoing trials NSCLC)
$諾和諾德(NVO.US)$ to acquire Cardior Pharmaceuticals
⇒ 1.025 B euros deal 💰💰
⇒ strengthens pi...
• $Axsome Therapeutics(AXSM.US)$ +39.1% (received from FDA proposed labeling for the its AXS-05 product candidate with respect to its New Drug Application for AXS-05 for the treatment of major depressive disorder)
• $Capricor Therapeutics(CAPR.US)$ +4% (announces statistically significant clinical benefits in skeletal muscle function in non-ambulant duchenne muscular dystrophy patients treated with CAP-1002 in HOPE-2 Open L...
• $Companhia Brasileira De Distribuicao(CBD.US)$ : BofA Securities Upgrades to Buy from Underperform - PT $5.25
• $赫氏(HXL.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $65 (from $45)
• $IPG光電(IPGP.US)$ : Citigroup Upgrades to Buy from Neutral - PT $157
• $Livent(LTHM.US)$ : Cowen Upgrades to Outperform from Market Perform - PT $33 (from $25)
• $Premier(PINC.US)$ : Piper Sandler Upgrades to Overweight from Neutral - PT $45 (from $...
暫無評論